Share on StockTwits

Equities research analysts at Citigroup Inc. initiated coverage on shares of athenahealth (NASDAQ:ATHN) in a research note issued to investors on Tuesday, reports. The firm set a “buy” rating on the stock.

Shares of athenahealth (NASDAQ:ATHN) opened at 189.01 on Tuesday. athenahealth has a 52 week low of $82.01 and a 52 week high of $189.72. The stock has a 50-day moving average of $145.3 and a 200-day moving average of $126.9. The company has a market cap of $7.065 billion and a P/E ratio of 2667.00.

athenahealth (NASDAQ:ATHN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.12. The company had revenue of $171.60 million for the quarter, compared to the consensus estimate of $168.39 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 47.5% on a year-over-year basis. Analysts expect that athenahealth will post $1.08 EPS for the current fiscal year.

A number of other firms have also recently commented on ATHN. Analysts at Robert W. Baird raised their price target on shares of athenahealth from $135.00 to $255.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of athenahealth in a research note on Thursday, February 13th. They set a “sector perform” rating and a $180.00 price target on the stock. Finally, analysts at Cowen and Company upgraded shares of athenahealth from an “underperform” rating to a “market perform” rating in a research note on Thursday, February 13th. They now have a $186.00 price target on the stock, up previously from $123.00. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $160.20.

In other athenahealth news, Director Dev Ittycheria sold 2,000 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $181.17, for a total value of $362,340.00. Following the completion of the transaction, the director now directly owns 8,574 shares of the company’s stock, valued at approximately $1,553,352. The transaction was disclosed in a document filed with the SEC, which is available at this link.

athenahealth, Inc (NASDAQ:ATHN), is a business services company, which provides ongoing billing, clinical-related, and other related services to its customers.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.